[ad_1] BOTHELL, Wash .– ( BUSINESS SONGS ) – The second point above the boilerplate "About Tucatinib" should read: "ORR was 47 percent (n = 16/34)" (instead of "ORR was 47 percent …
Read More »
[ad_1] July 11, 2018 The results of the Phase 1b clinical trials published in JAMA Oncology are promising for the association of tucatinib (formerly ONT-380) with T-DM1 against HER2-positive breast cancer heavily …
Read More »
[ad_1]
Read More »
[ad_1] THOUSANDS of patients with high blood pressure and congestive heart failure will be forced to switch to a significantly more expensive drug after a generic drug has been removed from the …
Read More »
[ad_1] WASHINGTON – US researchers have reported in preclinical models that they can boost the immune responses of macrophages against cancer by using a self-assembled supramolecule. A study published Monday in the …
Read More »
[ad_1] Researchers report that in preclinical models they can boost immune responses of macrophages against cancer using a self-assembled supramolecule … Much research on cancer immunotherapy focus on the use of T …
Read More »
[ad_1] Details Published Tuesday, 03 July 2018 15:45 Scientists have devised a special type of drug that helps the body to eat and destroy cancer cells. stimulates the action of white blood …
Read More »
[ad_1] BALTIMORE, USA (AFP) – John Ryan is only one of the miracles that emerged from the Johns Hopkins Cancer Unit in Baltimore. An immunotherapy treatment – very effective in a minority …
Read More »